What Is SLU-PP-332? The Exercise-Mimetic ERR Agonist (Not a Peptide)
SLU-PP-332 is a lab-made ERR agonist, not a peptide. What preclinical exercise-mimetic research shows, FDA status, and why it is not approved for people.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Track your peptide protocols in PeptIQ
Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.
SLU-PP-332 is a synthetic small molecule, not a peptide. It activates estrogen-related receptors (ERRα, ERRβ and ERRγ), nuclear proteins that help switch on genes for mitochondrial metabolism and endurance-style exercise responses. Researchers at Saint Louis University and collaborators developed it as an "exercise mimetic," meaning a drug that pushes some of the same biology as aerobic training in animal models.
There is no FDA-approved medicine containing SLU-PP-332, and ClinicalTrials.gov lists no registered human trials for it as of October 2026. Almost all published data are in mice. Online posts that treat it like a finished fat-loss or endurance product are ahead of the evidence.
This PeptIQ.io guide explains what SLU-PP-332 is, how it differs from mitochondrial peptides such as MOTS-c and SS-31, what preclinical studies have reported, and why side-effect questions cannot be answered yet in people. It contains no dosing information and no sources to buy from. Talk to a licensed clinician before using any research chemical or unapproved compound.
What SLU-PP-332 Is (and What It Is Not)
The name sounds like a peptide catalog entry, but the chemistry is different. SLU-PP-332 is a small molecule made in a lab. It is not a chain of amino acids and it is not something your body produces on its own.
Researchers describe it as a pan-agonist at the estrogen-related receptors ERRα, ERRβ and ERRγ. Despite the word "estrogen" in the name, these receptors are not the same as estrogen hormone receptors used in breast cancer medicine. They are orphan nuclear receptors that sit in the cell nucleus and regulate genes tied to mitochondria, fatty acid oxidation and oxidative muscle fibers.
The compound was developed in the Burris/Elgendy research groups (Saint Louis University, Washington University and University of Florida collaborators appear on recent papers). A 2026 structure–activity review in the International Journal of Biological Macromolecules calls SLU-PP-332 a "well-established exercise mimetic and widely used chemical probe for ERR activation" in research labs. That is a probe for scientists, not a product label for consumers.
01 / Not a peptide
Same feed, different chemistry
Social posts often file SLU-PP-332 next to MOTS-c and SS-31. The biology overlaps at mitochondria; the molecules and regulatory paths do not.
SLU-PP-332
MOTS-c
SS-31
Molecule type
Synthetic small molecule
Mitochondrial peptide
Designed peptide
Primary target
ERR nuclear receptors
Metabolic signaling pathways
Cardiolipin (inner membrane)
FDA-approved drug
None
None
Barth syndrome only (elamipretide)
Typical online label
Exercise mimetic powder
Research peptide vial
Mitochondrial peptide
Human trial registry (Oct 2026)
No ClinicalTrials.gov hits
Some metabolic pilots
Multiple disease trials
SLU-PP-332 is not a peptide. Sources: PubMed 41850449, 36988910; ClinicalTrials.gov search Oct 2026; FDA elamipretide approval context for Barth syndrome. Educational only.
Why People Call It an "Exercise Mimetic"
Exercise training changes gene expression in muscle: more mitochondria, better fatty acid use, improved endurance. ERR proteins, especially ERRα, sit on that pathway alongside the co-activator PGC-1α.
A landmark 2023 paper in ACS Chemical Biology reported that SLU-PP-332 triggers an ERRα-dependent acute response similar to aerobic exercise in mice and improves exercise capacity on treadmill testing. A follow-up in the Journal of Pharmacology and Experimental Therapeutics tested diet-induced obese and genetically obese mouse models and reported increased energy expenditure, higher fatty acid oxidation, less fat mass gain and improved insulin sensitivity.
Those results are why social feeds nicknamed it "exercise in a pill." The fair translation is narrower: in mice, under research conditions, the compound pushed metabolic gene programs that overlap with training. Mice are not people. Oral bioavailability, toxicity, drug interactions and real-world endurance were not established in that work.
03 / ERR pathway
Exercise biology without a workout
ERR agonists aim at transcription factors that exercise also engages. That overlap is why the compound is called an exercise mimetic in papers.
1
Aerobic exercise (reference)
Training activates PGC-1α and ERR programs that build oxidative capacity.
2
SLU-PP-332 (preclinical)
Synthetic ERRα/β/γ agonism shifts transcription toward mitochondrial and fatty-acid genes in rodent studies.
3
Downstream biology (research)
More oxidative fibers, higher fatty acid oxidation, improved treadmill endurance in mice — not established in people.
Simplified educational map, not a dosing model. PubMed 36988910, 37739806. ERR = estrogen-related receptor.
How SLU-PP-332 Differs From MOTS-c and SS-31
Mitochondrial conversations online often lump SLU-PP-332 with peptides. The mechanisms diverge.
SLU-PP-332
MOTS-c
SS-31 (elamipretide)
Type
Synthetic small molecule
Mitochondrial-derived peptide
Designed peptide
Main lever
ERR nuclear receptors (gene transcription)
Metabolic signaling (including AMPK-linked pathways in research)
Cardiolipin in the inner mitochondrial membrane
Human medicine status
None; preclinical only
No FDA-approved drug; compounding scrutiny
FDA accelerated approval for Barth syndrome only (narrow indication)
Typical online framing
"Exercise mimetic" / fat loss
GLP-1 stack partner
Mitochondrial support
PeptIQ.io's mitochondrial peptide research primer covers MOTS-c and SS-31 in depth. SLU-PP-332 belongs in the same conversation about metabolism, but not in the same regulatory or evidence bucket.
Stacking language ("add SLU to retatrutide") is forum fiction until controlled human studies exist. Our GLP-1 mechanism guide separates approved medicines from research compounds.
What the Evidence Actually Shows
The evidence pyramid for SLU-PP-332 is almost entirely preclinical.
02 / Evidence ladder
Wide base, empty top
Mouse endurance headlines fill social feeds. The human rung is still missing.
Receptor and cell assaysERR binding and gene expression characterized
Rodent metabolism and endurancePublished mouse models; not human outcome trials
Human pharmacology or safety trialsNo ClinicalTrials.gov registrations found Oct 2026
FDA-approved medicineResearch compound only
Preclinical signals are real in the literature; human clinical evidence is effectively absent. PubMed 36988910, 37739806, 41850449; ClinicalTrials.gov Oct 2026.
Cell and receptor work: Multiple papers characterize ERR binding, gene expression changes and analogues with improved drug-like properties (2026 SAR review).
Mouse metabolism and endurance: Papers cited above report metabolic and exercise-capacity phenotypes in rodent models (36988910, 37739806).
Other rodent models: Peer-reviewed work explores heart failure and kidney aging models with ERR agonism; those are hypothesis-generating, not treatment guides.
Human clinical trials: A search of ClinicalTrials.gov for "SLU-PP-332" returned no studies in October 2026.
Approved drug: None. openFDA and FDA drug databases contain no SLU-PP-332 product.
PeptIQ.io still hosts an older SLU-PP-332 complete guide aimed at protocol readers. This Kris-approved explainer is the non-dosing counterpart: use it for definitions and evidence, not for how much to take.
Side Effects, Safety and "Research Use" Products
Search demand clusters around "SLU-PP-332 side effects." The honest answer: there is no published human safety database to cite. Mouse studies are not toxicity trials in healthy volunteers. Unknown risks include cardiovascular effects, liver enzyme changes, hormone-sensitive tissues (ERR biology is complex) and interactions with medicines.
Products sold online as "research chemicals" are not held to pharmaceutical manufacturing standards. Identity, purity, and contaminants are recurring problems across the category. PeptIQ.io's source vetting checklist applies to any unapproved compound, peptide or not.
Authors on the 2026 SAR paper disclose cofounder relationships with Pelagos Pharmaceuticals, a company working on ERR drug discovery. That does not invalidate the science, but it explains why academic press releases and social hype can outpace clinical availability.
Sport, WADA and Fair-Play Context
Anti-doping scientists have already studied SLU-PP-332 because exercise mimetics are a known abuse category. A 2026 paper in Drug Testing and Analysis mapped in vitro human liver metabolites so laboratories could detect misuse. The introduction notes that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators in sport.
If you compete under anti-doping rules, an unapproved ERR agonist is not a gray-area supplement. It is prohibited territory. Recreational gym use still carries medical risk without a clinician.
FDA and Regulatory Status in 2026
SLU-PP-332 is not on FDA's list of approved drugs. It is not a dietary supplement ingredient with a lawful structure/function claim path for this molecule. PeptIQ.io's FDA tracker classifies it as research only for educational sorting, not as legal advice.
That puts it in the same broad bucket as many gray-market "metabolic research" powders: interesting biology, no regulatory clearance for human treatment. Clinicians and pharmacists can explain what is and is not compounding-eligible in your state; this article cannot.
How to Read SLU-PP-332 Claims Online
Four filters help:
Species: Mouse treadmill data does not prove a supplement works in you.
Molecule class: If a post calls it a peptide, the author has not read the primary literature.
Human data: Ask for a clinical trial NCT number. If none exists, "side effect" anecdotes are uncontrolled noise.
Comparison to GLP-1 drugs: Approved GLP-1 medicines went through massive phase 3 programs. SLU-PP-332 has not entered that path.
PeptIQ.io's Peptide Claim Auditor can sanity-check social posts that mention SLU-PP-332 alongside other compounds.
Talk to a Licensed Clinician
Metabolic goals (weight, endurance, energy) have approved paths: lifestyle medicine, registered dietitians, sports medicine, and prescription drugs with known benefit–risk profiles. Bring any product you are considering, its label, and lab paperwork if it exists.
If you already bought a research chemical, tell your clinician. Report suspected adverse events through FDA MedWatch. Do not treat forum stacks as medical care.
Frequently Asked Questions
Q: What is SLU-PP-332?
A: A synthetic small-molecule agonist at estrogen-related receptors (ERRα/β/γ), studied in labs as an exercise mimetic. It is not a peptide and not an approved drug.
Q: Is SLU-PP-332 FDA approved?
A: No. No FDA-approved product contains it, and ClinicalTrials.gov had no registered human trials for it in October 2026.
Q: Is SLU-PP-332 a peptide?
A: No. It is a small molecule. It is often discussed next to MOTS-c or SS-31 because all three touch mitochondrial metabolism, but the chemistry and regulation differ.
Q: What are SLU-PP-332 side effects in humans?
A: Unknown in a systematic way. Published safety data in people were not available in peer-reviewed sources we reviewed for this guide. Mouse studies do not establish a human side-effect profile.
Q: Does SLU-PP-332 work for fat loss or endurance?
A: Rodent studies reported metabolic and exercise-capacity changes under controlled conditions. That is not proof of benefit in humans, and products sold online are unregulated.
Q: Can I stack SLU-PP-332 with GLP-1 medicines?
A: No clinical interaction data exist. Combining unapproved research chemicals with prescription GLP-1 drugs is not evidence-based care. Use GLP-1 clinician access guidance for lawful options.
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.
